Sign inJoin waitlistJoin the waitlist

Paul Harmatz

Pediatric Gastroenterologist · UCSF Benioff Children’s Hospital Oakland

Credentials: · · · ·

History

UCSF Benioff Children’s Hospital Oakland
Present

Massachusetts General Hospital- MSO
1979–1982
Pediatrics
Ronald Reagan UCLA Medical Center
1976–1979
Geisel School of Medicine at Dartmouth
1972–1976

Research

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)
Genetics in Medicine · 2006 · 458 citations
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine…
The Journal of Pediatrics · 2006 · First of 18 authors · Corresponding · 278 citations
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease
British Journal of Haematology · 2006 · Last of 10 authors · 234 citations

Elliott Vichinsky
29 papers
Barbara Burton
26 papers
Joseph Muenzer
21 papers
KB
Kurt Bloch
20 papers
Chester Whitley
14 papers
WW
William Walker
14 papers
KB
Kenneth Berger
11 papers
Klane White
11 papers
RK
Ronald Kleinman
11 papers
Thomas Coates
10 papers
Julie Hoover-Fong
9 papers
Joel Charrow
8 papers

Grants

Pediatric Clinical Research Center
National Center for Research Resources · M01
Project lead · $898.2K · University of California, San Francisco
1997–2006
Transport of Iga Immune Complexes into Breast Milk
NIADDK · K08
Contact PI · $74.3K · Massachusetts General Hospital
1983–1986

Clinical trials

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
Principal investigator · Withdrawn · Phase 3
Chiesi Farmaceutici S.p.A.
2021
A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Principal investigator · Completed · Phase 1, Phase 2
Swedish Orphan Biovitrum
2019–2021
A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients
Principal investigator · Completed · Phase 1, Phase 2
Swedish Orphan Biovitrum
2018–2019
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Principal investigator · Completed · Phase 3
Ultragenyx Pharmaceutical Inc
2014–2016